Clinical trial
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney…
NCT00499135 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00499135 |
|---|---|
| Title | Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors |
| Official title | Pharmacodynamic Study of Sunitinib Malate in Patients With Renal Cell Cancer and Other Advanced Solid Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer |
| Intervention type | Drug, Other |
| Interventions | Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography, Sunitinib Malate |
| Enrollment | 25 |
| Start date | May 22, 2007 |
| Primary completion | May 14, 2014 |
| Completion | May 14, 2014 |
| First posted | Jul 11, 2007 |
| Last update posted | Oct 10, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: